NCT03853512

Brief Summary

In this study, researchers want to learn more about the effect of dexpanthenol dermal spray on skin recovery after a dermatological procedure (peeling) in the intimate area of women. After the peeling, participants will return within 3 weeks for 4 visits to the study center to investigate the skin conditions such redness, irritation, softness and possible side effects. In addition, study participants will be asked about their general acceptance of dexpanthenol dermal spray.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
33

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Feb 2019

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 12, 2019

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

February 15, 2019

Completed
10 days until next milestone

First Posted

Study publicly available on registry

February 25, 2019

Completed
16 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 13, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 13, 2019

Completed
Last Updated

March 11, 2020

Status Verified

March 1, 2020

Enrollment Period

29 days

First QC Date

February 15, 2019

Last Update Submit

March 10, 2020

Conditions

Keywords

Dermal sprayPeelingSkin hydrationConsumer satisfactionSensorial perception

Outcome Measures

Primary Outcomes (1)

  • Transepidermal water loss by TEWL probe

    The transepidermal water loss (TEWL) is measured in g m2 h-1 with a Tewameter TM300.

    Up to 23 days

Secondary Outcomes (7)

  • Skin properties of the participants

    Up to 23 days

  • Treatment satisfaction

    Up to 23 days

  • Product evaluation

    Up to 23 days

  • Number of adverse events by dermatological evaluation

    Up to 23 days

  • Number of adverse events by gynecological evaluation

    Up to 23 days

  • +2 more secondary outcomes

Study Arms (2)

Women_Inguinal side BAY207543

EXPERIMENTAL

Adult women apply BAY207543 to one side of the inguinal region, and semisolid vaseline to the the opposite side after skin peeling. The area with BAY207543 will be investigated.

Drug: BAY207543 (Bepanthol, Bepantol® Derma Spray)Other: Semisolid vaseline

Women_Inguinal side Vaseline

ACTIVE COMPARATOR

Adult women apply BAY207543 to one side of the inguinal region, and semisolid vaseline to the the opposite side after skin peeling. The area with the vaseline will be investigated.

Drug: BAY207543 (Bepanthol, Bepantol® Derma Spray)Other: Semisolid vaseline

Interventions

Product is applied to one side of the inguinal region.

Women_Inguinal side BAY207543Women_Inguinal side Vaseline

Product is applied to the other side of the inguinal region.

Women_Inguinal side BAY207543Women_Inguinal side Vaseline

Eligibility Criteria

Age18 Years - 60 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Phototypes I and II according to the Fitzpatrick scale;
  • Participants willing to have peeling in the genital area to improve the general appearance of the skin and bleaching of spots.

You may not qualify if:

  • Pathologies and/or skin injuries, such as psoriasis, sensitive skin, skin cancer, atopic dermatitis or other medical criteria to be considered at the time of evaluation
  • Hyperpigmentation in the test area that interfere with the evaluation of possible reactions (vascular malformations, scars, increase of pilosity and large amount of nevi)
  • Pathologies and/or active skin injuries (local and/or disseminated) in the evaluation area

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medcin Instituto da Pele

São Paulo, 06023-070, Brazil

Location

Related Links

MeSH Terms

Conditions

Consumer Behavior

Condition Hierarchy (Ancestors)

Behavior

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 15, 2019

First Posted

February 25, 2019

Study Start

February 12, 2019

Primary Completion

March 13, 2019

Study Completion

March 13, 2019

Last Updated

March 11, 2020

Record last verified: 2020-03

Locations